Norinchukin Bank The grew its holdings in Celgene Co. (NASDAQ:CELG) by 8.7% during the third quarter, HoldingsChannel reports. The firm owned 125,957 shares of the biopharmaceutical company’s stock after acquiring an additional 10,093 shares during the period. Norinchukin Bank The’s holdings in Celgene were worth $11,272,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CELG. Edgewood Management LLC lifted its stake in Celgene by 16.2% in the 2nd quarter. Edgewood Management LLC now owns 13,924,544 shares of the biopharmaceutical company’s stock worth $1,105,887,000 after purchasing an additional 1,943,607 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Celgene by 60.6% in the 2nd quarter. Renaissance Technologies LLC now owns 4,129,438 shares of the biopharmaceutical company’s stock worth $327,960,000 after purchasing an additional 1,558,600 shares in the last quarter. FMR LLC lifted its stake in Celgene by 14.8% in the 2nd quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock worth $648,067,000 after purchasing an additional 1,051,528 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd purchased a new position in Celgene in the 3rd quarter worth approximately $79,931,000. Finally, Chevy Chase Trust Holdings Inc. purchased a new position in Celgene in the 2nd quarter worth approximately $51,914,000. 73.72% of the stock is currently owned by institutional investors and hedge funds.

Celgene stock opened at $69.63 on Thursday. Celgene Co. has a fifty-two week low of $69.36 and a fifty-two week high of $110.81. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. The company has a market capitalization of $49.66 billion, a P/E ratio of 10.18, a P/E/G ratio of 0.44 and a beta of 1.53.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. On average, sell-side analysts expect that Celgene Co. will post 7.45 EPS for the current year.

Several analysts have recently commented on CELG shares. Leerink Swann set a $112.00 price target on shares of Celgene and gave the company a “hold” rating in a research report on Friday, October 26th. BidaskClub lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 10th. Zacks Investment Research lowered shares of Celgene from a “hold” rating to a “sell” rating in a research report on Wednesday, July 18th. Morgan Stanley lifted their price target on shares of Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a research report on Friday, July 27th. Finally, Mizuho reaffirmed a “buy” rating and set a $129.00 price target on shares of Celgene in a research report on Tuesday, July 31st. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $117.91.

WARNING: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/11/15/norinchukin-bank-the-grows-holdings-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Day Trading

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.